Featured Clinical Trials - Lymphoma

The clinical research mission of the Lymphoma Program at Dana-Farber Brigham Cancer Center is to make the treatment of lymphoid malignancies more effective and targeted, while reducing toxicities. The program makes promising new therapies available to patients with a variety of lymphoid malignancies at every stage of disease, in a carefully monitored setting, through clinical trials.

The program’s research currently focuses on several areas, including:

• Targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides.
• Targeting the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response.

Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.

Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.

To make a referral to one of the below clinical trials, please call: 617-632-6246

Chronic Lymphocytic Leukemia (CLL)

Watchful Waiting

Trial 17-105: A pilot study of a personalized neoantigen cancer vaccine with and without low-dose cyclophosphamide or pembrolizumab in treatment-naïve, asymptomatic patients with IGHV unmutated chronic lymphocytic leukemia
Principal Investigator: Inhye Ahn, MD

Trial 22-597: Randomized, phase 3 Study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with CLL: EVOLVE CLL study
Principal Investigator: Inhye Ahn, MD

Newly-Diagnosed

Trial 25-236:  A Phase 1/2 open-label study to investigate the safety of sonrotoclax ramp-up schedule(s) in adult patients with hematological malignancies
Principal Investigator: Matthew Davids, MD, MMSc
Relapsed/Refractory

Trial 21-712: A multicenter, open-label, phase 2 study to evaluate the efficacy and safety of venetoclax- obinutuzumab retreatment in patients with recurring chronic lymphocytic leukemia
Principal Investigator: Matthew Davids, MD, MMSc

Trial 24-449: Randomized trial of venetoclax + rituximab/obin w/ or w/o roginolisib, novel PI3K-delta inhibitor
Principal Investigator: Jennifer Brown, MD, PhD

Trial 21-414: An open label phase 1a/b dose escalation followed by dose expansion safety and tolerability trial of CAP-100, A Humanized C-C-Chemokine receptor 7 antibody, administered as monotherapy in subjects with R/R chronic lymphocytic leukemia
Principal Investigator: Jennifer Brown, MD, PhD

Trial 24-444: A phase 1/2 open-label multi-centre master protocol to evaluate the safety and efficacy of AZD0486 monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies
Principal Investigator: Matthew Davids, MD, MMSc

Richter’s Transformation

Trial 23-429: A phase 2 study of glofitamab as monotherapy or in combination with atezolizumab and/or polatuzumab vedotin in patients with Richter's Syndrome
Principal Investigator: Christine Ryan, MD

Diffuse Large B-Cell Lymphoma (DLBCL)

Newly-Diagnosed

Trial 24-754: A phase 3, multicenter, randomized, open label study comparing the efficacy and safety of glofitamab (Ro7082859) in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-Chp) versus Pola-R-Chp in previously untreated patients with large b-cell lymphoma (SKYGLO)
Principal Investigator: David Qualls, MD

Trial 22-467: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc
 
Transformed Follicular Lymphoma, Marginal Zone Lymphoma, or Other Transformed Indolent Lymphomas

Trial 22-606: A phase 2 study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma
Principal Investigator: Jennifer Crombie, MD

Relapsed/Refractory

Trial 24-253: A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Principal Investigator: David Qualls, MD

Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
Principal Investigator: David Qualls, MD

Trial 22-451: A phase 2/3 multicenter, open-label, randomized, active-control study of zilovertamab vedotin (MK-2140) in combination with standard of care in participants with   relapsed or refractory diffuse large B-cell lymphoma. (waveLINE-003)
Principal Investigator: Philippe Armand, MD, PhD

Follicular Lymphoma

Newly-Diagnosed

Trial 22-702: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma
Principal Investigator: Reid Merryman, MD

Relapsed/Refractory

Trial 24-393: A phase 2 study of epcoritamab, zanubrutinib, and rituximab (EZR) for treatment of relapsed or refractory follicular lymphoma or marginal zone lymphoma
Principal Investigator: Reid Merryman, MD

Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
Principal Investigator: David Qualls, MD

Histiocyte Disorders

Trial 22-548: A phase 2 study to assess the safety and efficacy of cobimetinib in refractory Langerhans cell histiocytosis, LCH-associated neurodegenerative disease, and other histiocytic disorders
Principal Investigator: Eric Jacobsen, MD

Hodgkin Lymphoma

Newly-Diagnosed

Trial 23-553: A randomized phase 3 interim response adapted trial comparing standard therapy with immunooncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma.
Principal Investigator: Ann S. LaCasce, MD, MMSc

Relapsed/Refractory

Trial 22-121: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed/refractory classical Hodgkin lymphoma
Principal Investigator: Philippe Armand, MD, PhD

Mantle Cell Lymphoma (MCL)

Newly-Diagnosed

Trial 24-654: A randomized phase 2 study of bendamustine, rituximab, cytarabine (AraC) induction with zanubrutinib (BRAZAN) followed by zanubrutinib/rituximab +/- sonrotoclax maintenance in treatment-naïve mantle cell lymphoma

Principal Investigator: Christine Ryan, MD

Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma
Principal Investigator: Austin Kim, MD

Relapsed/Refractory

Trial 24-104: Pilot study of glofitamab and lenalidomide in patients with relapsed or refractory mantle cell lymphoma previously treated with a BTK inhibitor
Principal Investigator: Christine Ryan, MD

Trial 21-124: A multi-center single arm phase 2 study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc

Trial 25-264: A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator: Christine Ryan, MD

Marginal Zone Lymphoma (MZL)

Relapsed/Refractory

Trial 24-393: A phase 2 study of epcoritamab, zanubrutinib, and rituximab (EZR) for treatment of relapsed or refractory follicular lymphoma or marginal zone lymphoma
Principal Investigator: Reid Merryman, MD

Primary Mediastinal Large B Cell Lymphoma (PMBCL)

Trial 23-179: A phase 2 trial of pembrolizumab in combination with chimeric antigen receptor therapy in patients with relapsed/refractory primary mediastinal B-cell lymphoma
Principal Investigator: Jennifer Crombie, MD

T-cell Lymphoma Clinical Trials

Relapsed/Refractory

Trial 22-248: Phase 1 multicenter study of ruxolitinib and duvelisib in relapsed or refractory T- or NK-cell lymphomas
Principal Investigator: Eric Jacobsen, MD

Trial 24-165: A phase 2 study evaluating the efficacy of ruxolitinib in patients with T-cell large granular lymphocytic leukemia (T-LGLL)
Principal Investigator: Eric Jacobsen, MD

Trial 24-459: An open-label, multi-center, non-randomized phase 1 dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell lymphoma
Principal Investigator: Eric Jacobsen, MD